Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role
The knowledge of BRCA status offers a chance to evaluate the role of the intraperitoneal route in patients selected by biomolecular profiles after primary cytoreduction surgery in advanced ovarian cancer. We performed a retrospective, multicenter study to assess oncological outcomes depending on adj...
Gespeichert in:
| Veröffentlicht in: | European journal of surgical oncology 2024-04, Vol.50 (4), p.108263-108263, Article 108263 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108263 |
|---|---|
| container_issue | 4 |
| container_start_page | 108263 |
| container_title | European journal of surgical oncology |
| container_volume | 50 |
| creator | Padilla-Iserte, Pablo Iváñez, Maria Muruzabal, Juan Carlos Navarro, Rafael Díaz-Feijoo, Berta Iacoponi, Sara García-Pineda, Virginia Díaz, Cristina Utrilla-Layna, Jesús Gil-Moreno, Antonio Serra, Anna Gilabert-Estellés, Juan Martínez Canto, Cristina Tejerizo, Álvaro Lago, Víctor Cárdenas-Rebollo, José Miguel Domingo, Santiago |
| description | The knowledge of BRCA status offers a chance to evaluate the role of the intraperitoneal route in patients selected by biomolecular profiles after primary cytoreduction surgery in advanced ovarian cancer.
We performed a retrospective, multicenter study to assess oncological outcomes depending on adjuvant treatment (intraperitoneal [IP] vs intravenous [IV]) and BRCA status (BRCA1/2 mutated vs. BRCA wild type [WT]). The primary endpoint was to determine progression-free survival. The secondary objectives were overall survival and toxicity.
A total of 288 women from eight centers were included: 177 in the IP arm and 111 in the IV arm, grouped into four arms according to BRCA1/2 status. Significantly better PFS was observed in BRCA1/2-mutated patients with IP chemotherapy (HR: 0.35; 95% CI, 0.16–0.75, p = 0.007), which was not present in BRCA1/2-mutated patients with IV chemotherapy (HR: 0.65; 95% CI, 0.37–1.12, p = 0.14). Significantly better OS was also observed in IP chemotherapy (HR: 0.17; 95% CI, 0.06–043, p |
| doi_str_mv | 10.1016/j.ejso.2024.108263 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2958294060</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0748798324003159</els_id><sourcerecordid>2958294060</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-2a90e6c46e9bf3e36a6e7bc278d3c24750f2aefe76db949a70e36543204fb2cd3</originalsourceid><addsrcrecordid>eNp9kE1L7TAQhoMoevz4A3dxydJNj2mSJo3cjR78AkEQXYc0nWoObXNM0gP-e1OO16WrYWaeeWEehP6UZFmSUlysl7COfkkJ5XlQU8H20KKsGC1oWcl9tCCS14VUNTtCxzGuCSGKSXWIjljNFa2oWCD7NFrf-zdnTY_9lKwfIGLfYTemYDYQXPIj5J19h8Gnd8jDz7zEpt2a0UKL_dYEZ0Zs5zZc4uvn1RUepmSS8yMOvodTdNCZPsLZdz1Br7c3L6v74vHp7mF19VhYRmQqqFEEhOUCVNMxYMIIkI2lsm6ZpVxWpKMGOpCibRRXRpLMVJxRwruG2padoPNd7ib4jwli0oOLFvrejOCnqKmqaqo4ESSjdIfa4GMM0OlNcIMJn7okepar13qWq2e5eic3H_39zp-aAdqfk_82M_BvB0D-cusg6GgdzJZcAJt0691v-V9xlIxi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2958294060</pqid></control><display><type>article</type><title>Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Padilla-Iserte, Pablo ; Iváñez, Maria ; Muruzabal, Juan Carlos ; Navarro, Rafael ; Díaz-Feijoo, Berta ; Iacoponi, Sara ; García-Pineda, Virginia ; Díaz, Cristina ; Utrilla-Layna, Jesús ; Gil-Moreno, Antonio ; Serra, Anna ; Gilabert-Estellés, Juan ; Martínez Canto, Cristina ; Tejerizo, Álvaro ; Lago, Víctor ; Cárdenas-Rebollo, José Miguel ; Domingo, Santiago</creator><creatorcontrib>Padilla-Iserte, Pablo ; Iváñez, Maria ; Muruzabal, Juan Carlos ; Navarro, Rafael ; Díaz-Feijoo, Berta ; Iacoponi, Sara ; García-Pineda, Virginia ; Díaz, Cristina ; Utrilla-Layna, Jesús ; Gil-Moreno, Antonio ; Serra, Anna ; Gilabert-Estellés, Juan ; Martínez Canto, Cristina ; Tejerizo, Álvaro ; Lago, Víctor ; Cárdenas-Rebollo, José Miguel ; Domingo, Santiago ; SEGO Spain-GOG Group</creatorcontrib><description>The knowledge of BRCA status offers a chance to evaluate the role of the intraperitoneal route in patients selected by biomolecular profiles after primary cytoreduction surgery in advanced ovarian cancer.
We performed a retrospective, multicenter study to assess oncological outcomes depending on adjuvant treatment (intraperitoneal [IP] vs intravenous [IV]) and BRCA status (BRCA1/2 mutated vs. BRCA wild type [WT]). The primary endpoint was to determine progression-free survival. The secondary objectives were overall survival and toxicity.
A total of 288 women from eight centers were included: 177 in the IP arm and 111 in the IV arm, grouped into four arms according to BRCA1/2 status. Significantly better PFS was observed in BRCA1/2-mutated patients with IP chemotherapy (HR: 0.35; 95% CI, 0.16–0.75, p = 0.007), which was not present in BRCA1/2-mutated patients with IV chemotherapy (HR: 0.65; 95% CI, 0.37–1.12, p = 0.14). Significantly better OS was also observed in IP chemotherapy (HR: 0.17; 95% CI, 0.06–043, p < 0.0001), but was not present in IV chemotherapy in relation with BRCA mutation (HR: 0.52; 95% CI, 0.22–1.27, p = 0.15). For BRCA WT patients, worse survival was observed regardless of the adjuvant route used. The IP route was more toxic compared to the IV route, but toxicity was equivalent at the long-term follow-up.
This retrospective study suggests that BRCA status can help to offer an individualized, systematic treatment after optimal primary surgery for advanced ovarian cancer, but is limited by the small sample size. Prospective trials are essential to confirm these results.</description><identifier>ISSN: 0748-7983</identifier><identifier>EISSN: 1532-2157</identifier><identifier>DOI: 10.1016/j.ejso.2024.108263</identifier><identifier>PMID: 38492526</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>BRCA mutation ; BRCA1 Protein - genetics ; BRCA2 Protein - genetics ; Carcinoma, Ovarian Epithelial ; Female ; Humans ; Intraperitoneal chemotherapy ; Mutation ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - surgery ; Overall survival ; Primary cytoreductive surgery ; Prospective Studies ; Recurrence-free survival ; Retrospective Studies</subject><ispartof>European journal of surgical oncology, 2024-04, Vol.50 (4), p.108263-108263, Article 108263</ispartof><rights>2024</rights><rights>2024 Published by Elsevier Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-2a90e6c46e9bf3e36a6e7bc278d3c24750f2aefe76db949a70e36543204fb2cd3</cites><orcidid>0009-0009-3303-3224 ; 0000-0002-7535-057X ; 0000-0001-8426-262X ; 0000-0003-0524-6213 ; 0000-0002-7350-4985 ; 0000-0002-6451-1817 ; 0000-0003-1106-5590 ; 0000-0002-4034-0873 ; 0000-0002-3093-1688 ; 0000-0002-0314-1752</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejso.2024.108263$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38492526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Padilla-Iserte, Pablo</creatorcontrib><creatorcontrib>Iváñez, Maria</creatorcontrib><creatorcontrib>Muruzabal, Juan Carlos</creatorcontrib><creatorcontrib>Navarro, Rafael</creatorcontrib><creatorcontrib>Díaz-Feijoo, Berta</creatorcontrib><creatorcontrib>Iacoponi, Sara</creatorcontrib><creatorcontrib>García-Pineda, Virginia</creatorcontrib><creatorcontrib>Díaz, Cristina</creatorcontrib><creatorcontrib>Utrilla-Layna, Jesús</creatorcontrib><creatorcontrib>Gil-Moreno, Antonio</creatorcontrib><creatorcontrib>Serra, Anna</creatorcontrib><creatorcontrib>Gilabert-Estellés, Juan</creatorcontrib><creatorcontrib>Martínez Canto, Cristina</creatorcontrib><creatorcontrib>Tejerizo, Álvaro</creatorcontrib><creatorcontrib>Lago, Víctor</creatorcontrib><creatorcontrib>Cárdenas-Rebollo, José Miguel</creatorcontrib><creatorcontrib>Domingo, Santiago</creatorcontrib><creatorcontrib>SEGO Spain-GOG Group</creatorcontrib><title>Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role</title><title>European journal of surgical oncology</title><addtitle>Eur J Surg Oncol</addtitle><description>The knowledge of BRCA status offers a chance to evaluate the role of the intraperitoneal route in patients selected by biomolecular profiles after primary cytoreduction surgery in advanced ovarian cancer.
We performed a retrospective, multicenter study to assess oncological outcomes depending on adjuvant treatment (intraperitoneal [IP] vs intravenous [IV]) and BRCA status (BRCA1/2 mutated vs. BRCA wild type [WT]). The primary endpoint was to determine progression-free survival. The secondary objectives were overall survival and toxicity.
A total of 288 women from eight centers were included: 177 in the IP arm and 111 in the IV arm, grouped into four arms according to BRCA1/2 status. Significantly better PFS was observed in BRCA1/2-mutated patients with IP chemotherapy (HR: 0.35; 95% CI, 0.16–0.75, p = 0.007), which was not present in BRCA1/2-mutated patients with IV chemotherapy (HR: 0.65; 95% CI, 0.37–1.12, p = 0.14). Significantly better OS was also observed in IP chemotherapy (HR: 0.17; 95% CI, 0.06–043, p < 0.0001), but was not present in IV chemotherapy in relation with BRCA mutation (HR: 0.52; 95% CI, 0.22–1.27, p = 0.15). For BRCA WT patients, worse survival was observed regardless of the adjuvant route used. The IP route was more toxic compared to the IV route, but toxicity was equivalent at the long-term follow-up.
This retrospective study suggests that BRCA status can help to offer an individualized, systematic treatment after optimal primary surgery for advanced ovarian cancer, but is limited by the small sample size. Prospective trials are essential to confirm these results.</description><subject>BRCA mutation</subject><subject>BRCA1 Protein - genetics</subject><subject>BRCA2 Protein - genetics</subject><subject>Carcinoma, Ovarian Epithelial</subject><subject>Female</subject><subject>Humans</subject><subject>Intraperitoneal chemotherapy</subject><subject>Mutation</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Overall survival</subject><subject>Primary cytoreductive surgery</subject><subject>Prospective Studies</subject><subject>Recurrence-free survival</subject><subject>Retrospective Studies</subject><issn>0748-7983</issn><issn>1532-2157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1L7TAQhoMoevz4A3dxydJNj2mSJo3cjR78AkEQXYc0nWoObXNM0gP-e1OO16WrYWaeeWEehP6UZFmSUlysl7COfkkJ5XlQU8H20KKsGC1oWcl9tCCS14VUNTtCxzGuCSGKSXWIjljNFa2oWCD7NFrf-zdnTY_9lKwfIGLfYTemYDYQXPIj5J19h8Gnd8jDz7zEpt2a0UKL_dYEZ0Zs5zZc4uvn1RUepmSS8yMOvodTdNCZPsLZdz1Br7c3L6v74vHp7mF19VhYRmQqqFEEhOUCVNMxYMIIkI2lsm6ZpVxWpKMGOpCibRRXRpLMVJxRwruG2padoPNd7ib4jwli0oOLFvrejOCnqKmqaqo4ESSjdIfa4GMM0OlNcIMJn7okepar13qWq2e5eic3H_39zp-aAdqfk_82M_BvB0D-cusg6GgdzJZcAJt0691v-V9xlIxi</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Padilla-Iserte, Pablo</creator><creator>Iváñez, Maria</creator><creator>Muruzabal, Juan Carlos</creator><creator>Navarro, Rafael</creator><creator>Díaz-Feijoo, Berta</creator><creator>Iacoponi, Sara</creator><creator>García-Pineda, Virginia</creator><creator>Díaz, Cristina</creator><creator>Utrilla-Layna, Jesús</creator><creator>Gil-Moreno, Antonio</creator><creator>Serra, Anna</creator><creator>Gilabert-Estellés, Juan</creator><creator>Martínez Canto, Cristina</creator><creator>Tejerizo, Álvaro</creator><creator>Lago, Víctor</creator><creator>Cárdenas-Rebollo, José Miguel</creator><creator>Domingo, Santiago</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0009-3303-3224</orcidid><orcidid>https://orcid.org/0000-0002-7535-057X</orcidid><orcidid>https://orcid.org/0000-0001-8426-262X</orcidid><orcidid>https://orcid.org/0000-0003-0524-6213</orcidid><orcidid>https://orcid.org/0000-0002-7350-4985</orcidid><orcidid>https://orcid.org/0000-0002-6451-1817</orcidid><orcidid>https://orcid.org/0000-0003-1106-5590</orcidid><orcidid>https://orcid.org/0000-0002-4034-0873</orcidid><orcidid>https://orcid.org/0000-0002-3093-1688</orcidid><orcidid>https://orcid.org/0000-0002-0314-1752</orcidid></search><sort><creationdate>202404</creationdate><title>Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role</title><author>Padilla-Iserte, Pablo ; Iváñez, Maria ; Muruzabal, Juan Carlos ; Navarro, Rafael ; Díaz-Feijoo, Berta ; Iacoponi, Sara ; García-Pineda, Virginia ; Díaz, Cristina ; Utrilla-Layna, Jesús ; Gil-Moreno, Antonio ; Serra, Anna ; Gilabert-Estellés, Juan ; Martínez Canto, Cristina ; Tejerizo, Álvaro ; Lago, Víctor ; Cárdenas-Rebollo, José Miguel ; Domingo, Santiago</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-2a90e6c46e9bf3e36a6e7bc278d3c24750f2aefe76db949a70e36543204fb2cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>BRCA mutation</topic><topic>BRCA1 Protein - genetics</topic><topic>BRCA2 Protein - genetics</topic><topic>Carcinoma, Ovarian Epithelial</topic><topic>Female</topic><topic>Humans</topic><topic>Intraperitoneal chemotherapy</topic><topic>Mutation</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Overall survival</topic><topic>Primary cytoreductive surgery</topic><topic>Prospective Studies</topic><topic>Recurrence-free survival</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Padilla-Iserte, Pablo</creatorcontrib><creatorcontrib>Iváñez, Maria</creatorcontrib><creatorcontrib>Muruzabal, Juan Carlos</creatorcontrib><creatorcontrib>Navarro, Rafael</creatorcontrib><creatorcontrib>Díaz-Feijoo, Berta</creatorcontrib><creatorcontrib>Iacoponi, Sara</creatorcontrib><creatorcontrib>García-Pineda, Virginia</creatorcontrib><creatorcontrib>Díaz, Cristina</creatorcontrib><creatorcontrib>Utrilla-Layna, Jesús</creatorcontrib><creatorcontrib>Gil-Moreno, Antonio</creatorcontrib><creatorcontrib>Serra, Anna</creatorcontrib><creatorcontrib>Gilabert-Estellés, Juan</creatorcontrib><creatorcontrib>Martínez Canto, Cristina</creatorcontrib><creatorcontrib>Tejerizo, Álvaro</creatorcontrib><creatorcontrib>Lago, Víctor</creatorcontrib><creatorcontrib>Cárdenas-Rebollo, José Miguel</creatorcontrib><creatorcontrib>Domingo, Santiago</creatorcontrib><creatorcontrib>SEGO Spain-GOG Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Padilla-Iserte, Pablo</au><au>Iváñez, Maria</au><au>Muruzabal, Juan Carlos</au><au>Navarro, Rafael</au><au>Díaz-Feijoo, Berta</au><au>Iacoponi, Sara</au><au>García-Pineda, Virginia</au><au>Díaz, Cristina</au><au>Utrilla-Layna, Jesús</au><au>Gil-Moreno, Antonio</au><au>Serra, Anna</au><au>Gilabert-Estellés, Juan</au><au>Martínez Canto, Cristina</au><au>Tejerizo, Álvaro</au><au>Lago, Víctor</au><au>Cárdenas-Rebollo, José Miguel</au><au>Domingo, Santiago</au><aucorp>SEGO Spain-GOG Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role</atitle><jtitle>European journal of surgical oncology</jtitle><addtitle>Eur J Surg Oncol</addtitle><date>2024-04</date><risdate>2024</risdate><volume>50</volume><issue>4</issue><spage>108263</spage><epage>108263</epage><pages>108263-108263</pages><artnum>108263</artnum><issn>0748-7983</issn><eissn>1532-2157</eissn><abstract>The knowledge of BRCA status offers a chance to evaluate the role of the intraperitoneal route in patients selected by biomolecular profiles after primary cytoreduction surgery in advanced ovarian cancer.
We performed a retrospective, multicenter study to assess oncological outcomes depending on adjuvant treatment (intraperitoneal [IP] vs intravenous [IV]) and BRCA status (BRCA1/2 mutated vs. BRCA wild type [WT]). The primary endpoint was to determine progression-free survival. The secondary objectives were overall survival and toxicity.
A total of 288 women from eight centers were included: 177 in the IP arm and 111 in the IV arm, grouped into four arms according to BRCA1/2 status. Significantly better PFS was observed in BRCA1/2-mutated patients with IP chemotherapy (HR: 0.35; 95% CI, 0.16–0.75, p = 0.007), which was not present in BRCA1/2-mutated patients with IV chemotherapy (HR: 0.65; 95% CI, 0.37–1.12, p = 0.14). Significantly better OS was also observed in IP chemotherapy (HR: 0.17; 95% CI, 0.06–043, p < 0.0001), but was not present in IV chemotherapy in relation with BRCA mutation (HR: 0.52; 95% CI, 0.22–1.27, p = 0.15). For BRCA WT patients, worse survival was observed regardless of the adjuvant route used. The IP route was more toxic compared to the IV route, but toxicity was equivalent at the long-term follow-up.
This retrospective study suggests that BRCA status can help to offer an individualized, systematic treatment after optimal primary surgery for advanced ovarian cancer, but is limited by the small sample size. Prospective trials are essential to confirm these results.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>38492526</pmid><doi>10.1016/j.ejso.2024.108263</doi><tpages>1</tpages><orcidid>https://orcid.org/0009-0009-3303-3224</orcidid><orcidid>https://orcid.org/0000-0002-7535-057X</orcidid><orcidid>https://orcid.org/0000-0001-8426-262X</orcidid><orcidid>https://orcid.org/0000-0003-0524-6213</orcidid><orcidid>https://orcid.org/0000-0002-7350-4985</orcidid><orcidid>https://orcid.org/0000-0002-6451-1817</orcidid><orcidid>https://orcid.org/0000-0003-1106-5590</orcidid><orcidid>https://orcid.org/0000-0002-4034-0873</orcidid><orcidid>https://orcid.org/0000-0002-3093-1688</orcidid><orcidid>https://orcid.org/0000-0002-0314-1752</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0748-7983 |
| ispartof | European journal of surgical oncology, 2024-04, Vol.50 (4), p.108263-108263, Article 108263 |
| issn | 0748-7983 1532-2157 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2958294060 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | BRCA mutation BRCA1 Protein - genetics BRCA2 Protein - genetics Carcinoma, Ovarian Epithelial Female Humans Intraperitoneal chemotherapy Mutation Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - surgery Overall survival Primary cytoreductive surgery Prospective Studies Recurrence-free survival Retrospective Studies |
| title | Oncological outcomes of intraperitoneal chemotherapy in advanced ovarian cancer: BRCA mutation role |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A42%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oncological%20outcomes%20of%20intraperitoneal%20chemotherapy%20in%20advanced%20ovarian%20cancer:%20BRCA%20mutation%20role&rft.jtitle=European%20journal%20of%20surgical%20oncology&rft.au=Padilla-Iserte,%20Pablo&rft.aucorp=SEGO%20Spain-GOG%20Group&rft.date=2024-04&rft.volume=50&rft.issue=4&rft.spage=108263&rft.epage=108263&rft.pages=108263-108263&rft.artnum=108263&rft.issn=0748-7983&rft.eissn=1532-2157&rft_id=info:doi/10.1016/j.ejso.2024.108263&rft_dat=%3Cproquest_cross%3E2958294060%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2958294060&rft_id=info:pmid/38492526&rft_els_id=S0748798324003159&rfr_iscdi=true |